The molecular blood typing, grouping and infectious disease NAT market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to reach at an estimated value of USD 1,359.95 by 2028 and grow at a CAGR of 8.11% in the above-mentioned forecast period. Increase in the government interventions has risen the market for molecular blood typing acts as the major factor drives the molecular blood typing, grouping and infectious disease NAT market.
Blood group typing is defined as a mandatory testing procedure before blood transfusions to measure blood compatibility between the donor and the recipient, as well as for the determination of the Rh factor.
Rise in the population all over the globe is the vital factor escalating the market growth, also increase in disposable income, rise in the advanced technology, increase in the research and development activities, increase in the healthcare expenditures and rise in the demand for molecular typing tests are the major factors among others driving the molecular blood typing, grouping and infectious disease NAT market. Moreover, rise in the technological advancements and modernization in the healthcare devices and rise in the emerging markets will further create new opportunities for molecular blood typing, grouping and infectious disease NAT market in the forecasted period of 2021-2028.
The countries covered in the molecular blood typing, grouping and infectious disease NAT market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Read Full Report Summary @ https://www.databridgemarketresearch.com/reports/global-molecular-blood-typing-grouping-and-infectious-disease-nat-market
North America dominates the molecular blood typing, grouping and infectious disease NAT market due to high and advanced technology and rise in the research and development activities in this region.
The major players covered in the molecular blood typing, grouping and infectious disease NAT market report are Abbott, BD, Danaher, Biokit S.A, bioMérieux SA, Bio-Rad Laboratories, Inc., Laboratory Corporation of America Holdings, Mediapilote, DiaSorin S.p.A, Grifols, S.A, Fujirebio, Hologic Inc., Immucor, Inc., Ortho Clinical Diagnostics, Proteome Sciences, Quidel Corporation, Tecan Trading AG, Siemens and Thermo Fisher Scientific Inc. among other domestic and global players.
About Data Bridge Market Research, Private Ltd
Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.
Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”
Contact:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
